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Abstract
Clostridium difficile infection, an increasingly prevalent and virulent condition, is often resistant to treatment. Standard
antibiotic therapy is rarely efficient when used to treat recurrent C. difficile infection. Fecal microbiota transplantation
(FMT) is a safe, effective and inexpensive treatment that has a cure rate of about 90%, according to clinical trials and
reports. This approach may also be applicable in treating ulcerative colitis, a type of inflammatory bowel disease, on the
basis of the restoration of flora imbalances. Additionally, recent data suggests that a disproportion in composition of the
gut microbiome may contribute to obesity. FMT, may restore a healthy balance. Using information from Touro College’s
database, this article discusses the reason behind the success of fecal microbiota transplantation when used to treat
Clostridium difficile infection and ulcerative colitis. The effect of diet, environment and geography on the bacterial flora
is also explored.
Introduction
The human gut microbiome consists of over 100 trillion microbial cells, exceeding the amount of human cells by a factor of 10.
Bacteria are found in various parts of the body including nasal
passages, oral cavity, skin, urogenital system and the gastrointestinal tract. The gut microbiota carries out a variety of valuable
tasks for their human hosts; it assists in the development of innate and adaptive immunity, serves as an energy source, and kills
foreign organisms. (Dave, et al. 2012). The quality and composition of the gut microbiome depends largely on diet, medication
and weight of its host. The microbiota is capable of secreting
or altering the production of molecules that affect both weight
gain or loss and fat mass. (Rosenbaum, et al. 2015)
Colonization of the microbial microflora of the internal and
external surfaces in a human begins at birth and is termed indigenous bacterial microflora. (Van der Waaij, 1989) The route
of delivery when a baby is born determines which type of bacteria will develop. Infants delivered vaginally have microbiota
comparable to their own mother’s vagina, whereas infants born
via Cesarean section develop microbes similar to the bacteria
found on the skin surface. (Dominguez-Bello, et al. 2010) After
birth, microbes develop and colonize, benefitting both themselves and their host, each contributing something vital to the
other. (Van der Waaij 1989) For example, the anaerobic bacteria in our distal gut breaks down complex polysaccharides and
ferments the resulting monosaccharides into short chain fatty
acids. This is a mutually beneficial relationship; the microbes live
in a sheltered anaerobic environment and receive a rich assortment of glycans while offering the host a source of carbon and
energy. (Backhed, et al. 2005)
Of all the microbial communities being studied by human microbiome researchers, the gastrointestinal tract (GI) holds a promising future for the discovery of new concepts and therapies.
The large colon holds the most abundant and diverse communities of microbes; it has both local and systemic effects on the
body. (Dave et al. 2012) The gut microbiota can be thought of as
a “microbial organ placed within a host organ,” it plays vital roles

in metabolism and immune system function. It is known that
the microbial communities have a method of communication;
they also can consume, store and redistribute energy. (Bakhed,
et al. 2005)
Fecal Microbiota Transplantation (FMT) is an FDA experimental
drug targeted to treat Clostridium difficile associated diseases
(CDAD). It has been successfully used to treat patients with ulcerative colitis (UC) and different forms of inflammatory bowel
diseases (IBD). Additionally, by comparing and analyzing the
gut microbiome of lean and obese individuals, researchers have
been able to hypothesize a cause for obesity and other weight
issues. Using this knowledge, microbiologists can manipulate
the microbiome and formulate a therapy to decrease obesity
worldwide. This research can result in a new kind of pharmacopeia; implanting a more refined probiotic to combat infection,
inflammation and dysbiosis.

Methods and Materials
To investigate the mechanism of fecal bacteriotherapy and how
it can be utilized to treat Clostridium difficile associated diseases and other gastrointestinal disorders, many original research
articles and reviews have been read. Touro College’s online database was employed, particularly EBSCO, PubMed, ProQuest
and Google scholar. Further research was done by perusing
the footnotes and references in review papers to find original
research.

Discussion
Fecal Microbiota Transplantation
The indigenous microbiota is vital to the human host, yet it
can be altered by various factors of modern day life, most
commonly repeated doses of antibiotics. (Van der Waaij, 1989).
Dethlefsen et al. tested the fecal microbiota of adults before
and after oral administration of ciprofloxacin for five days using
pyrosequencing. A rapid reduction in richness of bacterial phyla
was seen, resulting in decreased diversity, fullness and balance
in the microbiome. Four weeks following the completion of
the antibiotic, the microbiota returned to baseline. However,
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in some individuals, it took 6 months for the bacterial phyla to
completely return to normal. (Dethlefsen et al., 2008) Infectious
diseases of the past were thought to be linked with bacteria capable of causing disease in a susceptible host. However, present
day infectious diseases are linked to host interaction with potentially pathogenic bacteria that make up the microflora of the
digestive tract (Van der Waaij, 1989). A particular infection that
results from a disruption of the gut microbiota is Clostridium
difficile infection. Clostridium difficile is an anaerobic, spore
forming bacillus that produces 2 exotoxins that damage the intestinal mucosa. It is the most commonly recognized cause of
anti-microbial associated diarrhea. Clostridium difficile associated disease mainly affects the large colon, causing diarrhea and
pseudomembranous colitis. If progressed, the infection can lead
to toxic megacolon, sepsis and death (McDonald et al., 2006).
The microbial colonies that regularly control the Clostridium
difficile communities are inhibited and blocked by antibiotics.
Because C. difficile spores are generally resistant to antibiotics,
this allows them to germinate back into their vegetative state
after antibiotic treatment has ended. If the remaining microbes
in the intestine cannot get rid of the infection, Clostridium difficile can multiply and release the toxins that return the disease
symptoms. (Bakken et al., 2011)
There are different treatments that exist for recurrent
Clostridium difficile infection, many of which involve the use
of stronger antibiotics, such as vancomycin and metronidazole. However, as Dr. Johan Bakken says, “the use of antibiotics represents a double-edged sword by suppressing both the
pathogen as well as the protective microbiota.” In other words,
repeated and extended uses of antibiotics have negative effects
on the natural gut flora. It is a possible risk factor for further
infection due to the continuously altered state of gut microbes.
(Bakken et al. 2011)
Another approach to treat recurrent Clostridium difficile infection is to restore the damaged microbial communities using
probiotics. Saccharomyces bouldarii is a yeast that colonizes in
the colon within 3 days of ingestion, survives gastric acids of
the stomach and is cleared from the colon once treatment is
discontinued. The effectiveness of the probiotic as an add-on
to antibiotics was tested in two trials. The treatment did not
decrease recurrence rates in those with their first episode of
Clostridium difficile infection but it did decrease the frequency of relapses in those with the recurrent infection. The second trial showed effectiveness only in patients that were on
a high dose of vancomycin. (McFarland et al., 1994) (Bakken
et al., 2011) Thus, probiotics may have a role in treatment of
Clostridium difficile infection, but their effectiveness is less than
ideal. (Kelly, LaMont 2008)
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Fecal Bacteriotherapy, or fecal microbiota transplantation
(FMT), is an innovative and effective treatment for Clostridium
difficile infection and other infections of the colon, including ulcerative colitis. It involves implanting stool from a healthy donor
into a recipient’s diseased colon, thereby allowing a newer and
healthier microbiome to develop and flourish. From the trials
done and the case studies reported, it seems that recurrent
Clostridium difficile infection can be cured with a single treatment of FMT. The logic behind FMT is straightforward: strong
antibiotics can cause an imbalance in the normal intestinal flora
and reduce colonization resistance, which allows C. difficile to
grow and cause symptoms of infection.With the introduction of
healthy donor feces, the imbalance can be corrected, the cycle
interrupted and the normal colon function returns. (Bakken, et
al. 2011)
Although the first four patients to be treated with FMT in the
20th century was in 1958 for pseudomembranous enterocolitis,
(Bakken, et al. 2011) the use of fecal material as a treatment
for diseases dates back more than 2500 years ago in ancient
China. During the Dong-jin dynasty in the 4th century China, Ge
Hong, a well-known doctor described the use of human fecal
suspension by mouth for people suffering from severe diarrhea
or food poisoning. This treatment was considered a medical
miracle that brought patients back from the brink of death. In
the 16th century, during the Ming dynasty, Li Shizen prescribed
a series of fecal material doses to treat abdominal diseases that
caused severe diarrhea, fever, pain, vomiting, and constipation.
This treatment was called “yellow soup” for aesthetic reasons.
(Zhang, et al. 2012)
Nowadays however, the procedure is done in a more sterilized
manner and reported to have been successful via colonoscopy
(Persky, Brandt 2010), nasogastric tube, (Aas, et al. 2003) nasoduodenal tube, (van Nood, et al. 2013) and self-administered
fecal enemas. (Silverman, et al. 2010) One method of implantation was not found to be superior over the other. (Rohlke,
Stollman 2012)
Currently, the only FDA approved drug to treat C. difficile infection is the antibiotic vancomycin, which is inadequate for patients suffering from recurrent CDI. It is estimated that 80% of
patients treated with the standard antibiotic therapy are cured,
however, the remaining 20% are likely to recur 3-28 days after
discontinuation of antibiotics. Disease caused by C. difficile has
been shown to increase the length of stay of patients by a mean
of 7 days, incurring an additional $10,500 in health care charges
for every infected patient. (McFarland, et al. 1994) Alternative
treatments, including probiotics, surgery and administration of
different antibiotics, have been suggested, but none were effective, safe and inexpensive. Fecal microbiota transplant seems to
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fit the criteria of being inexpensive, highly effective and safe. In
fact, a study done to compare 4 different treatments for CDAD;
metronidazole, vancomycin, fidaxomicin and FMT demonstrated that FMT was the “most cost-effective strategy.” The incremental cost-effectiveness ratio (ICER) was $17, 016 relative to
oral vancomycin. (Konijeti, et al. 2014) It is “the only therapy
that restores the phylogenic richness of the recipient’s intestinal
microbiota without prolonging the perturbation of the normal
microbiotic composition.” (Bakken, et al. 2011)
A study comparing the fecal material of a patient before and
after FMT illustrates the effectiveness of the transplant. Before
FMT, the patient’s fecal material was composed of atypical bacterial populations including Veillonella, Clostrudium, Lactobacillus,
and Streptococcus. Two weeks after FMT, Bacteroidetes began
to appear and four weeks after the transplant, the stool studies were culture negative for C. difficile. The recipient’s fecal
bacterial composition greatly resembled the donor. Throughout
the months following FMT the patient reported issues of loose
stool, but those issues were resolved within two weeks without
therapy. Six months later, the patient was completely cured from
C. difficile infection. (Khoruts, et al. 2010)
Further data is needed to assess the effectiveness of FMT, yet
given the promising data to date and anticipated research data
on the intestinal microbiome, it seems to be the most reasonable treatment for recurrent C. difficile infection (CDI). Bakken
et al. put together a guideline for the proper administration of
FMT. Included in the guideline is a detailed description of primary indication, donor selection and directions for preparing and
administering the stool. Many trials and studies that involving
FMT used this guideline as instructions on how to proceed. In
order to be eligible for FMT, a patient either has to have recurrent or relapsing CDI with at least three episodes of mild-moderate CDI and a failure of a 6-8 week taper with vancomycin.
Patients on major immunosuppressive agents, decompensated
liver cirrhosis or have had a recent bone marrow transplant
cannot receive the fecal microbiota transplant as it may cause
adverse effects.
Currently, little or no data is available to suggest that any reasons, other than the exclusion criteria based on medical history
and laboratory testing, would recommend a specific donor over
another. However, using intimate contacts as donors minimizes
the risk of transmitting an infectious disease. Donors are interviewed thoroughly and must answer a detailed questionnaire
regarding their past medical history. Donors are disqualified
if they test positive for HIV, Hepatitis B or C infections or had
exposure to HIV or viral hepatitis. Individuals that have high
risk sexual behaviors, use illicit drugs, had tattoo or body piercing within 6 months or have a history of incarceration cannot

donate stool for FMT. Once a donor passes the medical and laboratory tests, their stool is screened for enteric pathogens such
as C. difficile toxin A and B, fecal Giardia and Cryptosporidium
antigens and Helicobacter pylori fecal antigen. (Bakken, et al.
2011)
The stool donor may or may not take an osmotic laxative the
night before the procedure.The stool should be used as soon as
possible, preferably within 6 hours. The choice of diluents may
vary among practitioners, but either preservative-free normal
saline or 4% milk is combined with the stool in a household
blender. It should be mixed until it reaches a homogenous slurry consistency and filtered to remove particulate. The slurry
stool mixture is to be used immediately. The optimal volume
for transplantation has not been established yet; however if by
nasogastric tube or via other routes from above, smaller volumes (25-50 mL) should be used and if by colonoscopy or other
routes from below, larger volumes (250-500 mL) may be used.
(Bakken et. al. 2011)
This is a basic outline on how a practitioner would administer
fecal microbiota transplant. However, “practical and aesthetic
barriers” have slowed down the widespread use of FMT, despite
its success in dramatically resolving CDI after one treatment.
Enrollment and screening of donors is a tedious process linked
with substantial costs, thereby inhibiting the use of FMT in severe situations. Youngster et al. suggests that by establishing a
repository of prescreened frozen donor stool, this treatment
may be more easily obtainable from a broader population. He
conducted a trial to evaluate the efficacy of FMT in treating
relapsing CDI in a pilot cohort of 20 patients, comparing colonoscopic and nasogastric tube administration.
The donors for the study underwent extensive physical examinations and general laboratory screening tests to ensure that all
results were within normal range for age and sex. Renal function
and electrolytes, complete blood count with differential, complete
liver function tests and fecal occult blood testing were some of
the tests that fecal donors underwent. All fecal donations were
set aside for four weeks to allow retesting of donors for HIV and
hepatitis B and C before the feces was inoculated.To facilitate manipulation of the fecal material, donors were asked to take milk
of magnesia the day before the donation. The feces was mixed in
a commercial blender with normal saline and then were passed
through 4 sieves to get rid of any particulate. The final product
was concentrated 3-fold by centrifugation and then resuspended
in sterile saline with 10% glycerol added as a cytoprotectant. The
resulting mixture was frozen at -80°C. Each filtered sample was
calculated to have come from 41g of fecal material. Inocula were
stored frozen for up to 156 days and thawed in a 37°C water
bath, then kept on ice until delivery.
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Patients were ordered to stop taking antibiotics for 2 days before the procedure. Recipients designated for a colonoscopic
administration underwent a standard bowel preparation with
4 liters of polyethylene glycol electrolyte solution. Then, 90 cc
of the thawed inoculum was placed in the right colon via endoscopy. The fecal material was further diluted to 250 cc for
adults and 160 cc for pediatric recipients. Patients were given
a single dose of loperamide at the time of the procedure in
order to retain the material for as long as possible. The patients assigned to nasogastric tube administration were given
omeprazole orally for 2 days before the procedure, to ensure
that the fecal bacteria will not be affected by the acids in the
stomach. After inserting the nasogastric tube, 90 cc of inoculum
was administered. In order to minimize vomiting and aspiration,
the inoculum was not diluted. (Youngster, et al. 2014)
The goal of the trial was the clinical resolution of diarrhea off
antibiotics for C. difficile infection, without a recurrent episode
within 8 weeks. Patients who showed no improvement were
offered a second FMT by their preferred route of administration, using the same donor inoculum to minimize exposure to
infectious agents.
Of the 20 patients in both study arms, 14 were cured after the
first FMT; 8 of them were in the colonoscopy group and 6 in the
nasogastric tube group. One patient refused a second transplant
but the remaining 5 patients were given a second infusion via
NGT using feces from their original donors. Four patients were
cured after the second FMT, resulting in an overall cure rate of
90%. No patient relapsed within the 8 week period following
the initial cure.
There were some serious adverse effects that were deemed
unrelated to the trial by investigators and the Institutional review board, which may have been caused by the poor health
of the patients with recurrent CDI. 2 patients died; one from
an obstructive pulmonary disease and another from metastatic
laryngeal cancer. A third patient was diagnosed with adenocarcinoma of the esophagus and a fourth (treated via NGT) was
hospitalized for Fourier gangrene.
This trial demonstrated that the transplantation of unrelated
frozen donor stool is effective in treating recurrent CDI with
an overall cure rate of 90%. Additionally, NGT appears to be a
feasible route of administration for elderly patients with the
infection. One 89 year old female patient had 16 documented
cases of CDI in the previous 15 months. She was hospitalized
4 times and placed on the intensive care unit twice due to the
infection. After two infusions, she was cured and was free from
any symptoms of the disease off treatment for 12 months.
(Youngster, et. al. 2014)
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Seeing the success with frozen inocula, Youngster et al. directed another study evaluating the effectiveness of oral capsulized
frozen fecal microbiota transplantation in treating relapsing C.
difficile infection. The donors were thoroughly screened, as
described in the previous study (and the guideline by Bakken,
et al. 2011) and similar processing of the fecal material took
place.To ensure that the acidic environment of the stomach will
not destroy the capsule, commercially available acid-resistant
hypromellose capsules were used. The stability of the capsules
was tested by mimicking the acidic environment of the stomach.
Trypan blue filled capsules were used, at a temperature of 37°C
and a pH of 3 or less, and the capsules were stable for 115
minutes before the dye was released.
From July 2013 through January 2014, a total of 20 patients
were treated using stool obtained from four donors. The recipients followed up six months later in July 2014. The goal of the
study was the clinical resolution of diarrhea, while not receiving
antibiotic for C. difficile, without relapse within 8 weeks.
The procedure went as follows: each patient was given 15 capsules, directly from an investigator on 2 consecutive days. 2 days
prior to FMT, patients were ordered to stop all antibiotics. They
were asked to fast 4 hours prior to and 1 hour post taking the
capsule for both days. If there was no improvement after 72
hours, patients were retested and offered another treatment
for positive test results.
From the 20 patients treated, 14 had clinical resolution of diarrhea after the first FMT. The remaining 6 patients were retreated 7 days after the first procedure. 5 of the 6 had resolution of
diarrhea after the second FMT, however one patient relapsed
within the 8 week follow up time period. Thus the overall rate
of diarrheal resolution was 90%. (Youngster et. al. 2014)
Fecal microbiota transplantation used to treat C. difficile infection is a highly effective, safe and inexpensive method as described studies and research. Very few, if not any, complications
were caused by FMT. The fecal material can be manipulated and
can be transplanted as a liquid via NGT or colonoscopy and can
also be ingested as a capsule. FMT is currently an FDA experimental drug and therefore the trials and studies are with small
samples and lack of placebo or other trial to compare. Granted,
the trials and studies done are encouraging, however this may
be due to the small sample size. Furthermore, even with careful
screening, there is a potential risk of transmission of infections
via microbiota transplantation. Larger studies would be needed
to confirm these outcomes and to evaluate long-term safety
and effectiveness. (Youngster et. al 2014)

Mechanism of Fecal Bacteriotherapy

Fecal Microbiota Transplant for Ulcerative Colitis
Encouraged by the success for fecal microbiota transplant in
the treatment of C. difficile infection, researchers looked to
other conditions related to GI microbial imbalance, such as
inflammatory bowel disease (IBD), obesity and diabetes mellitus. (Borody, et al. 2103) Inflammatory bowel diseases are
thought to be caused by an overall community dysbiosis rather than a single underlying pathogen. In patients with IBD, an
increase in Actinobacteria and Proteobacteria and a decrease
of Lachnospiraceae, Bacteroidetes, Clostridium leptum, and
Bifidobacteria are observed. (Clemente, et. al. 2012)
Ulcerative colitis (UC), a type of IBD, is a chronic devastating
inflammatory bowel disease that affects the large intestine.
Unfortunately, the current medications used to treat UC have
significant adverse effects; they mainly target the inflammation
without focusing on the dysbiosis. (Kunde, et al. 2013) The
colonic microbiome in UC patients lacks diversity and is dysfunctional. The cause of inflammation of the colon in UC is
hypothesized to be caused by inappropriate stimulation of the
innate mucosal immune system because of dysbiosis in a genetically susceptible individual. Borody et al. asks the following
question: C. difficile infection causes reduced microbial diversity
which results in symptoms of colitis; if FMT can reverse this,
perhaps a similar treatment can be used to treat ulcerative colitis? (Borody, et al. 2013)
Borody et. al. conducted a trial assessing the clinical, histological
and colonoscopic effects of “human probiotic infusion” (HPI), or
fecal material transplant in six selected patients with ulcerative
colitis. All patients had suffered from severe recurrent symptoms of UC and each, respectively, were on series of moderate
to high dose steroids and anti-inflammatory medications. The
donors were chosen by the recipient patients and screened
thoroughly to prevent any transmission of parasites or bacterial
pathogens. The feces (200–300 g) was diluted in 200 to 300
mL normal saline and administered to the patient via retention
enema within 10 minutes of its preparation. This process was
repeated daily for 5 consecutive days. One week following HPI,
some symptoms of ulcerative colitis had resolved in several patients. A complete reversal of symptoms was achieved in all
patients 4 months post HPI, by which all other UC medications
had been discontinued. From 1 to 13 years later, patients remained asymptomatic with a healthy colonoscopic appearance
and normal histology.
However, the pathogenesis of UC is unknown since it is characterized by persistent inflammation. It is suggested that the
disease is driven by a chronic infection caused by the absence
of vital luminal anaerobes. If the ability of the normal flora to
resist colonization by pathogens is hindered, for example, by

previous antibiotic use, the numbers of protective anaerobes in
the colon, such as Bacteroides, decrease. This would allow the
establishment of other pathogenic anaerobes or spore bearing
bacteria and a form of recurrent, chronic colitis.The persistence
of UC may be due to the implantation of spores in the mucosal
surface, analogous to Clostridium difficile infection. Antibiotics
may help briefly but are unlikely to be curative because the
spores are not eliminated. (Borody et. al. 2003)
Kunde et. al. conducted a pilot study to evaluate the efficiency
and safety of fecal microbiota transplantation in children with
ulcerative colitis. Ten children, ages 7 to 21 with mild to moderate UC according to the pediatric ulcerative colitis activity
index (PUCAI) were enrolled in the study. Clinical response and
improvement was defined as decrease in PUCAI by more than
15 points on the index. A decrease in PUCAI to less than 10
points was considered clinical remission. Each donor produced
a 90 gram stool sample every day which was blended with 250
mL normal saline and filtered through 2 gauze pieces to remove
sediments. It was then separated into 4 aliquots of 60 mL each
and kept in a warm water bath (37°) until administration. Each
patient received FMT as retention enema for 1 hour (60-mL
enema every 15 minutes) daily for 5 days. One subject however,
was not able to tolerate the retention enema for 3 consecutive
days and was therefore not included in the results. Within one
week following the procedure, 7 of the 9 subjects (78%) showed
clinical response. Four weeks after FMT, six of the nine patients
(67%) maintained the clinical response. However, 3 of the nine
subjects (33%) went into clinical remission one week following
FMT. All of the adverse events related to FMT, besides fever,
were self-limiting, and did not require intervention from health
care providers. The majority of them were similar to subjects’
baseline symptoms of UC such as bloating and diarrhea.
The dramatic response to FMT after one week was not achieved
in all subjects, perhaps due to the severity or duration of the
disease, or the ability to retain larger FMT volumes for longer
periods. Using FMT via fecal enema to treat UC in children is
feasible, as proved in the trial. However, the sample size was small
and therefore limits future indication. In order to improve FMT a
standardization procedure would need to be arranged for donor
selection and ideal routes of administration. (Kunde, et al. 2013)

The Gut Microbiota and Obesity
The World Health Organization (WHO) reports that in 2014,
more than 1.9 billion adults, 18 years and older were overweight
and of these, over 600 million were obese. Obesity is a growing,
worldwide epidemic that has been accompanied by increases in
obesity related disorders, including type II diabetes, hypertension
and nonalcoholic fatty liver disease. Much emphasis has been
placed on the dietary excess or host genes in obese individuals.
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Yet, in addition to increased calories or shifts in host metabolism,
the composition of the intestinal microbiota can contribute to
the progression of obesity. Both diet induced obesity and gene induced obesity have microbe independent and microbe dependent
pathways. (Baackhed et al. 2004, Cox, Blaser 2013)
A study was done to investigate the effect that diet has on shaping the gut microbiome. The fecal material of 15 European children and that of 14 children from a rural African village, Bukina
Faso were compared and tested with 16S rRNA sequencing,
and biochemical analysis. The goal of the study was to explore
three questions: the split of bacterial diversity between the two
populations, the connection between the gut microbiota and
diet, and the distribution of well-known bacterial pathogens
within the two populations given the different hygienic and geographic conditions.
The diet of Bukina Faso children is mostly vegetarian; rich in
plant polysaccharides, starch and fiber and low in fat and animal protein. All the food was grown and harvested nearby the
village by women. The European children were eating a typical
Western diet high in animal protein, sugar, starch and fat and
low in fiber. A dataset consisting of 438, 219 of filtered, high
quality, classifiable 16S rRNA was generated. Of all of the sequences in all the Bukina Faso and European samples 92.4%
were found to belong to the most populated bacterial phyla:
Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria.
However, it was the proportions that stood out: Actinobacteria
and Bacteroidetes were more abundant in the Bukina Faso children than the European children 10.1% versus 6.7% and 57.7%
versus 22.4%, whereas Firmicutes and Proteobacteria were represented more in EUROPEAN than BUKINA FASO children,
63.7% versus 27.3% and 6.7% versus 0.8%. Since Prevotella,
Xylanibaeter (Bacteroidetes) and Treponema (Spirochaetes)
were exclusively found in the Bukina Faso children. De Filippo
et. al. hypothesized that these 3 genera could be a result of high
fiber intake due to the environmental factors distinguishing the
two populations (diet, hygiene, climate and geography). Perhaps
these three groups contribute to the extraction of metabolic energy from ingested plant polysaccharides. It is reasonable
to deduce that the increase in the Firmicutes to Bacteroidetes
(F/B) ratio in European children possibly triggered by their
high-calorie diet might predispose them to future obesity. This
Firmicutes/Bacteroidetes ratio may also be considered a useful
obesity biomarker. (De Filippo, et al. 2010)
A study done by Turnbaugh et al. further demonstrates the
effect of diet on the gut microbiota. Mice raised in a germ free
environment without any exposure to microbes, and then colonized at specific life stages with different microbial communities are referred to as gnotobiotic animals. Adult human fecal
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microbiota was transplanted into the recipient mice to establish
a stable gut community similar their donors. An aliquot of the
fecal dilution was introduced by gavage to the 15 recipient mice.
These mice were maintained on a low fat plant polysaccharide
(LF/PP) rich diet and fecal samples were collected 1 day, 1 week
and 1 month after colonization. Half of the mice were then
switched to a high-sugar, high-fat Western diet. The LF/PP and
Western diet were maintained for 2 additional months, after
which the mice were killed. Results showed that when the diet
of the mice were switched from a LF/PP regimen to a highfat, high sugar “Western” diet the structure of the microbiota
was shifted within a single day. The representation of metabolic
pathways in the microbiome were changed and the microbiome gene expression was altered. The mice fed a Western diet
had an increased representation of the Erysipelotrichi class of
bacteria within the Firmicutes phylum relative to mice fed the
LF/PP diet. In mice that consumed a Western diet, the Bacilli,
another class of the Firmicutes was abundant and a significant
decrease in member of Bacteroidetes was found. These mice
increased adiposity, demonstrating that this trait is transmissible
via microbiota transplantation. Using germ free mice, researchers were able to see a clear correlation between the foods the
mice were fed and its effect on the composition of their gut
microbiota. Gnotobiotic technology is a promising tool for discovering new classes of probiotics that affect nutrient harvest in
a given diet. (Turnbaugh, et al.2008)
A study comparing the fecal material of 31 adult female monozygotic and 23 dizygotic twin pairs and their mothers, concordant
for obesity or leanness, was performed, to address how host
genotype, environmental exposures and host adiposity influence
the gut microbiome. All twins were 25-32 years old of European
or African ancestry. Analysis of 16S rRNA datasets produced
by the three PCR-based methods, plus shotgun sequencing of
community DNA, revealed a lower proportion of Bacteroidetes
and a higher proportion of Actinobacteria in obese versus lean
Europeanropean and African individuals. Overall, across many
methods, obesity was associated with a decrease in diversity
of the gut microbiota. “This reduced diversity suggests an analogy: the obese gut microbiota is not like a rainforest or reef,
which are adapted to high energy flux and are highly diverse,
but rather may be more like a fertilizer runoff where a reduced
diversity microbial community blooms with abnormal energy
input.” (Turnbaugh, et al. 2009)
There is an interesting case study regarding the transmission of
“obese bacteria.” A 32 year old female patient with recurrent
CDI elected to undergo FMT after many failed antibiotic therapies. Around the same time, she tested positive for Helicobacter
pylori.

Mechanism of Fecal Bacteriotherapy

The patient chose her 16 year old daughter, who was approximately 140 pounds to be her stool donor, and, subsequently, her
weight increased to 170 pounds. The patient herself was 136
pounds at the time of the transplant. The patient was retreated for H. pylori with metronidazole, tetracycline, bismuth and
proton pump inhibitor, and two weeks later she had the FMT.
Six hundred cc. of the suspension of the donor stool in sterile
water was infused through a colonoscope. The patient dramatically improved after the procedure and CDI did not recur.
However, 16 months later, the patient presented again, and reported an unintentional weight gain of 34 pounds. Despite a
medically supervised liquid protein diet and exercise program
she had been unable to lose weight. Her weight continued to
climb despite the diet and exercise and at 36 months post FMT
she weighed 177 pounds.
Alang and Kelly offer a several of hypotheses to explain the
rapid weight gain following FMT. There is a known link between
H. pylori treatment and weight gain, resulting from the increase
in appetite after the suppression of the bacteria.Yet, the patient
was never obese before FMT and the fact that the stool donor
also gained weight leads to the possibility that her obesity resulted from the transplant (Alang, Kelly 2014).
This hypothesis is supported in a study testing the fecal material of twins discordant for obesity. This experiment offers
an opportunity to examine connections between obesity and
its associated metabolic disorders, diet, and the gut microbiota. Ridaura et al. conducted a study by transplanting the fecal
material of twins discordant for obesity into mice in order to
replicate the donors’ microbiota community in the colon. The
impact of these differences on the body composition and metabolic phenotypes were able to be detected, and the effects
of diet-by-microbiota interactions analyzed. The mice harboring
the transplanted microbiomes from the obese twins exhibited
higher expression of microbial genes involved in detoxification
and stress responses, in biosynthesis of cobalamin and metabolism of essential amino acids. In contrast, the transplanted
microbiomes from lean co-twins exhibited higher expression
of genes involved in digestion of plant-derived polysaccharides,
fermentation to butyrate and propionate. The results suggest
that the transplanted microbiota of the lean co-twins had greater capacity to breakdown and ferment polysaccharides than the
microbiota of their obese co-twins. (Ridaura, et al. 2013)
From these studies, it is evident that the gut microbiota reflects
the health, diet and metabolism of its host. It seems that the composition of the phyla that make up the gut microbiome in healthy
individuals is properly balanced. However, a disrupted microbiome
can contribute to obesity by altering energy extraction from food.

Conclusion
By transplanting stool from a healthy donor into a recipient’s
diseased colon via fecal bacteriotherapy, a newer and healthier
microbiome can flourish and the function of the large intestine
can be restored. Fecal microbiota transplant has been proven
by many clinical trials to be a safe, effective and inexpensive
procedure. FMT has been successful in treating many cases C.
difficile infection, as well as ulcerative colitis and has a promising
future in the field of diet and obesity. The stool material can be
readily administered in different ways, as a slurry consistency
administered via colonoscopy or nasogastric tube, or packaged
in a pill and taken orally; this therapy is easily accessible to almost all populations.
However, one potential drawback of FMT is the small sample
size in many of the clinical trials done. Additionally, fecal bacteriotherapy may not be the ideal treatment for every individual
suffering with GI tract disorders, for example, it may not be
ideal in immunocompromised patients. However, FMT is an FDA
approved drug and will undergo further standardization regarding donors and the preparations and administration of the stool.
The future of the gut microbiota related treatment is an active
topic of research; much is anticipated from this exploration into
the microbiome.
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